Previous 10 | Next 10 |
NEW YORK , May 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participati...
NEW YORK , May 19, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that it will host a virtual R&am...
Applied DNA Sciences (NASDAQ: APDN ) +71% after receiving FDA emergency use authorization for COVID-19 test. More news on: Applied DNA Sciences, Inc., AIM ImmunoTech Inc., Immunic, Inc., Stocks on the move, , Read more ...
German regulators have signed off on a Phase 2 clinical trial evaluating Immunic's (NASDAQ: IMUX ) oral DHODH inhibitor IMU-838 in ~230 moderately ill COVID-19 patients across 10-35 sites in Europe and the U.S. More news on: Immunic, Inc., Healthcare stocks news, Stocks on the move, ...
NEW YORK , May 13, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has received first regulat...
Cellect Biotechnology (NASDAQ: APOP ) +126% on publication of ApoGraft data ahead of clinical trial. More news on: Cellect Biotechnology Ltd., MyoKardia, Inc., AMC Entertainment Holdings, Inc., Stocks on the move, , Read more ...
Immunic (NASDAQ: IMUX ): Q1 GAAP EPS of -$0.79 beats by $0.17 . More news on: Immunic, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK , May 8, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for t...
Immunic (NASDAQ: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, has closed a sale of 1,764,706 shares of common stock with certain institutional investors, led by Altium Ca...
Thinly traded micro cap Immunic (NASDAQ: IMUX ) slips 13% premarket on average volume in reaction to its direct sale of ~1.8M common shares at $8.50 per share to certain institutional investors. More news on: Immunic, Inc., Healthcare stocks news, Stocks on the move, , Re...
News, Short Squeeze, Breakout and More Instantly...
Immunic Inc. Company Name:
IMUX Stock Symbol:
NYSE Market:
--News Direct-- Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) in the peer-reviewed journal, Neurology...
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on May 8, 2024 – NEW YORK , May 1, 2024 /PRNewswire/ -- Immunic, ...
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation Immunic Announces Publication of Extended Data From Phase 2 ...